Zacks Research Comments on AEON Biopharma Q3 Earnings

AEON Biopharma, Inc. (NASDAQ:AEON) – Zacks Research issued their Q3 2026 earnings estimates for shares of AEON Biopharma in a research note issued on Monday, October 5th. Zacks Research analyst J. Vandermosten expects that the company will post earnings of ($0.13) per share for the quarter. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. Zacks Research also issued estimates for AEON Biopharma’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.11) EPS.

AEON has been the topic of several other reports. Laidlaw initiated coverage on shares of AEON Biopharma in a research note on Wednesday, September 9th. They set a “buy” rating and a $1.80 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $1.20 price target (down from $5.00) on shares of AEON Biopharma in a report on Friday, August 14th. Finally, Lake Street Capital reissued a “buy” rating and issued a $2.00 price objective (up from $1.00) on shares of AEON Biopharma in a report on Thursday, October 1st. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, AEON Biopharma has an average rating of “Moderate Buy” and a consensus price target of $1.67.

AEON Biopharma Stock Performance

AEON stock opened at $0.31 on Thursday. AEON Biopharma has a one year low of $0.18 and a one year high of $1.45. The firm’s fifty day moving average is $0.27 and its 200 day moving average is $0.58. The firm has a market cap of $15.53 million, a PE ratio of 1.73 and a beta of 0.69.

Insider Buying and Selling

In other news, major shareholder Timothy P. Lynch acquired 1,150,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was bought at an average cost of $0.21 per share, for a total transaction of $241,500.00. Following the purchase, the insider owned 6,500,000 shares in the company, valued at approximately $1,365,000. This represents a 21.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 9.40% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. Unlike companies that primarily target aesthetic uses, AEON is developing treatments for neurological and other medical conditions in which botulinum toxin may provide therapeutic benefits.

The company’s lead product candidate is ABP-450, an investigational botulinum neurotoxin type A complex licensed from Daewoong Pharmaceutical. AEON has evaluated ABP-450 in clinical programs targeting conditions including chronic migraine and cervical dystonia, and its broader development strategy may encompass additional therapeutic indications.